Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Contribute

España

India

Italia

대한민국

日本

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Research

My Stocks

Tools

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Trade Ideas

Unusual Options Activity

Heatmaps

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Calculators

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Joanne Wuensch

Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025

Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive

Medtronic Analysts Applaud Q1 Beat-And-Raise

Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive

Medtronic Analysts Applaud Q1 Beat-And-Raise

Johnson & Johnson Analyst: 3 Takeaways On Opioid Litigation

Wedbush Adds Boston Scientific To Top Picks, Sees Several Catalysts Ahead

Johnson & Johnson Analyst: 3 Takeaways On Opioid Litigation

Wedbush Adds Boston Scientific To Top Picks, Sees Several Catalysts Ahead

Johnson & Johnson Analysts Laud Accelerating Pharma Business

Nevro's C-Suite, Board Changes Should 'Mark The Turnaround Of The Organization,' BMO Says In Upgrade

Joanne Wuensch Recent News

Johnson & Johnson's Asbestos Woes: Experts Speak Up

IRhythm Technologies Is Breaking New Ground In Cardiac Monitoring, Says New Sell-Side Bull

BMO: Insulet On Track For Profitability In 2018

Becton Dickinson Has A Strong, Diverse Pipeline, But Is Fairly Valued, Says BMO Capital Markets

After Recent Run, Penumbra Downgraded On Fears Its Upside Is Exhausted

Abbott Laboratories Makes BMO Capital's Top Picks List

BMO On Abbott Labs: 'It's Likely Time For The Stock To Take A Pause'

Endologix Sees FDA Approval Of Nellix Remaining Elusive; BMO Downgrades

Potential 21% Upside Seen For Shares Of Recent IPO Penumbra

Cooper Companies Third Quarter Good, Not Great, Says BMO

Expect Conservative Guidance For Medical Tech Stocks?

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap